Altogen Labs CRO Services:
- PRE-CLINICAL RESEARCH SERVICES
- Pharmacology and Toxicology Testing: IC50 for Tumor Cell Lines
- Xenograft Animal Service: Immunocompromised NOD/SCID Mice
- Therapeutic RNAi Development: Targeted siRNA, qPCR Assays
- Liposome Encapsulation Services: siRNA, miRNA, DNA, Proteins
- ELISA and Cell-Based Assay Development (Cell Cycle, Viability)
- Apoptosis Assay: Caspase-3 and Caspase-7 Cell Line Screen
- RNAi Consulting: Technology Development and Evaluation
- GENERATION OF STABLE CELL LINES
- CELL BANKING SERVICES
- RNA INTERFERENCE (RNAi) SERVICES
- In Vivo siRNA Delivery and Tissue Targeting (In Vivo RNAi)
- siRNA Transfection and RNAi Cell-based Library Screening
- Generation of Tet-inducible RNAi Gene Knockdown Cell Lines
- RNAi Screen Pathway Analysis: siRNA and microRNA
- RNAi Manufacturing and CRO Services
- PCR Cloning: DNA Vector Construction (shRNA)
- Quantitation sh/siRNA-induced Knockdown by qRT-PCR and WB
- Genome-wide siRNA and microRNA High-throughput Screens
- Stable RNAi Cell Line Generation: Stable Gene Knockdown
- siRNA Liposome Encapsulation Service
- Transient (siRNA) and Stable (shRNA) Transfection Services
- BIOLOGY LABORATORY CRO SERVICES
- BIOREMEDIATION SERVICES
- MICROORGANISM ID SERVICE
In Vivo siRNA Delivery and Tissue Targeting (In Vivo RNAi)
In Vivo siRNA Delivery and Tissue Targeting
RNAi-induced gene silencing is used to study gene function in cultured cells (in vitro). However this approach does not allow a critical evaluation of gene function within the whole organism (in vivo). Unfortunately, application of RNAi in vivo present many technical challenges due to siRNA stability, delivery efficiency, biodistribution, and tissue targeting. The difficulties presented when performing RNAi experiments in animals can be laborious, time-consuming, expensive, and present numerous technical challenges. One of the key challenges faced using RNAi technology is the successful delivery of a stable and functional siRNA (or microRNA) to the target tissue. siRNA or miRNA must overcome degradation by nucleases, escape detection by the innate immune system, minimize off target effects and ultimately to be taken up by the target tissue. Altogen Labs has developed methods to prevent siRNA degradation in serum (chemical modification and encapsulation of siRNA), increase delivery efficiency to target organ, and produce strong tissue-targeted functional effect induced by siRNA in vivo.
Chemical modifications of siRNA or miRNA are performed to increase their stability in vivo. These chemical modifications sustain the potency, efficacy and specificity of the siRNA molecules and increase their overall stability in the dynamic environment of a living organism. Standard modifications include 2’MOE, FANA, 2’-Fluoro, LNA, and encapsulation into liposomes.
Two basic methods are adapted for RNAi use in vivo: administration of small interfering RNA (siRNA) and administration of plasmid DNA and viral vectors, which express a short hairpin RNA (shRNA) that is subsequently processed into active siRNA in vivo. In general, viral-based shRNA vectors provide the highest delivery efficiency in vivo, but are time-consuming to construct and have significant immunogenicity problem.
Altogen Labs provides complete in vivo siRNA development services including in vitro siRNA testing in cell-based assays, encapsulation and tissue-targeted siRNA delivery into animals (including various mouse and rat cancer disease models and xenograft animal models). Multiple siRNA administration routes local and systemic are possible: intravenous, intraperitoneal, intranasal, intratumoral, intratracheal, intradermal, intramuscular, intrathecal, intracerebellar, and intravascular perfusion.
Once we know the details of your project, we can provide you an immediate price quote (contact e-mail: info@altogenlabs.com or call Altogen Labs technical support at 512-433-6177). Please note that experimental details will help us to provide an accurate quote and timeline estimate.
see also: In Vivo siRNA Delivery and Tissue Targeting (In Vivo RNAi) | siRNA Transfection and RNAi Cell-based Library Screening | Generation of Tet-inducible RNAi Gene Knockdown Cell Lines | RNAi Screen Pathway Analysis: siRNA and microRNA | RNAi Manufacturing and CRO Services | PCR Cloning: DNA Vector Construction (shRNA) | Quantitation sh/siRNA-induced Knockdown by qRT-PCR and WB | Genome-wide siRNA and microRNA High-throughput Screens | Stable RNAi Cell Line Generation: Stable Gene Knockdown | siRNA Liposome Encapsulation Service | Transient (siRNA) and Stable (shRNA) Transfection Services